1,721,226 research outputs found
Queyrat's erythroplasia of the prepuce: a case-report.
No full textAbstract
A case of Queyrat's erythroplasia of the prepuce is reported. The Authors emphasize the precancerous role of the lesion because of its high frequency of malignant transformation. Local excision appears to be the only adequate form of treatment.
PMID: 4082852 [PubMed - indexed for MEDLINE
Combined renal and pyelic fusion with crossed ectopia of single ureter
No full textAbstract
A case of a forty-five-year-old woman with fused kidneys and intercommunicating pelves drained by a single ureter crossing the midline is reported. A review of the literature is presented.
PMID: 3532495 [PubMed - indexed for MEDLINE
Renal hydatid disease: report of 9 cases and discussion of urologic diagnostic procedures.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Conservative management of T1G3 transitional cell carcinoma of the bladder. Risk factor analysis in 165 selected patients
No full textINTRODUCTION AND OBJECTIVE: The management of TlG3 transitional cell carcinoma of the bladder (TCCB), is still controversial. Some Authors support an immediate radical cystectomy. BCG is considered the treatment of choice. Limited encouraging experiences are reported with intravesical chemotherapy.
Objectives; Evaluating a selected population of 165 patients with TlG3 TCCB, in absence of Tis, treated conservatively with TUR plus adjuvant intravesical therapy.
METHODS: Between January 1976 and December 1999, 165 patients with TlG3 bladder tumors were treated by TUR plus adjuvant intravesical therapy.
Patients with previuos T1G3, Tis, more than 3 tumors or greater than 3 em were excluded. A sequential combination of mitomycin C and epirubicin was adopted in
91 patients (55%). BCG or other agents were used intravesically in 28 (17%) and 46 (28%) patients respectively. In case of Ta-Tl recurrence, TUR was repeated and
one year of adjuvant intravesical therapy completed. Patients went off study if Tis or invasive tumor (T-category over TI) were detected. Age (less or more than 70),
previuos history, multiplicity, time to recurrence, adjuvant therapy were considered in multivariate analysis.
RESULTS: At a mean follow-up period of 48 months (12- 240 months), 74 patients (44.8%) recurred. The recurring tumor was Tl in 32 (19%) cases and TlG3 in 23 cases (14%). In 8 additional patients (5%) a Tis was detected. Fourteen patients (8.4%) progressed and 10 patients (6%) underwent cystectomy. Median progression-free survival was 149 months. Twenty-three patients (14%) died, 9 (5.5%) of whom due to bladder cancer. Median overall survival was 144 months, Recurrence was found related only to number of the tumors (p=0.0007) and to BCG (p=O.0013). No factor was found significantly correlated to progression. Previous history (p=0.0021), recurrence after adjuvant therapy (p<O.OOOl), and progression (p<O.OOOl),were statistically related to survival.
CONCLUSIONS; If no concomitant Tis exists a conservative approach is a legitimate option as an initial treatment of patients with primary TlG3 bladder tumors. Time to progression and overall survival are comparable to those obtained by cystectomy. Recurrence is statistically influenced by initial number of tumors and BCG therapy. Mortality is significantly higher in patients with previous bladder tumors and/or showing recurrence and progression
Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial
No full textPhosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Profile Question (SEP-Q) 2 and SEP-Q3; adverse events (AE) were also investigated after 3 months. A total of 65 patients with a median (25th-75th percentile) post-operative IIEF-5 score of 8 (7–9) were treated. Nine (13.8%) patients reported AE of mild/moderate grade and discontinued treatment. A significant IIEF-5 score median (25th-75th percentile) increase of 10 (0–12) was found after treatment in the other 56 patients (p <.001). Sildenafil 100 mg ODF was effective in ED after RP in terms of improved IIEF-5 score and improved SEP-Q2 and SEP-Q3 in 67.9% of patients. It could represent a valid alternative for those patients with low compliance to tablet intake
Radiological anatomy of the renal artery and its branches [L'anatomia radiologica dell'arteria renale e dei suoi rami]
No full text- …
